A four gene signature of chromosome instability (CIN4) predicts for benefit from taxanes in the NCIC-CTG MA21 clinical trial

Recent evidence demonstrated CIN4 as a predictive marker of anthracycline benefit in early breast cancer. An analysis of the NCIC CTG MA.21 clinical trial was performed to test the role of existing CIN gene expression signatures as prognostic and predictive markers in the context of taxane based che...

Descripción completa

Detalles Bibliográficos
Autores principales: Spears, Melanie, Lyttle, Nicola, D'Costa, Alister, Chen, Bingshu E., Yao, Cindy Q., Boutros, Paul C., Burnell, Margot, Levine, Mark N., O'Brien, Patti, Shepherd, Lois, Bartlett, John M.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226493/
https://www.ncbi.nlm.nih.gov/pubmed/27056899
http://dx.doi.org/10.18632/oncotarget.8542

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5226493/
https://www.ncbi.nlm.nih.gov/pubmed/27056899
http://dx.doi.org/10.18632/oncotarget.8542

Ejemplares similares